NCT05712122

Stellatar Ganglione Blockage for Ventricular Arrhytmias

Completed NA Last updated 3 February 2023

What this trial tests

NA trial testing stellate block in Cardiac Arrhythmia in 10 participants. Completed in 24 March 2022.

Timeline

1 January 2021

Primary endpoint
24 March 2022

24 March 2022

Quick facts

Lead sponsor	Adana City Training and Research Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 January 2021
Primary completion	24 March 2022
Estimated completion	24 March 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

• stellate block

Conditions studied

• Cardiac Arrhythmia — all drugs for Cardiac Arrhythmia →

Sponsor

Adana City Training and Research Hospital

Who can join

18 and older, any sex, with Cardiac Arrhythmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ventricular tachycardia (VT) and ventricular fibrillation (VF) are life-threatening conditions that increase in frequency over the years. An electrical storm (ES) is defined as the occurrence of 3 or more continuous ventricular arrhythmia. The sympathetic nervous system has an important role in VA and is the target of treatment. Studies show that stellate ganglion blockade (SGB) can reduce cardiac sympathetic tone and is an alternative bridge therapy in VAs. In our study, the investigators preferred to apply a combination of local anesthetic and steroid in the stellate ganglion blocking method to 10 VA patients who were resistant to medical treatment and had an ICD, and we also planned to examine the 6-month follow-up results of the patients.

In our study, USG-guided left stellate ganglion blockade was applied to 10 VA and ES patients with ICD. The 6-month results of the patients were evaluated retrospectively. For blockage, the solution was prepared by adding 8 mg dexamethasone, 40 mg lidocaine, and 10 mg bupivacaine to 10 mL with physiological saline. The success of the procedure was evaluated with the development of Horner's syndrome in the left eye.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.